Agios Pharmaceuticals: Q1 Earnings Snapshot
Agios Pharmaceuticals: Q3 Earnings Snapshot
Agios Pharmaceuticals: Q2 Earnings Snapshot
Interest in the company's AI platform continues to drive the stock.
The consensus price target hints at a 42.5% upside potential for Agios Pharmaceuticals (AGIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings...
Agios Pharmaceuticals (AGIO) reports encouraging first-quarter results, beating estimates for earnings and sales.
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 14.53% and 4.43%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Agios Pharmaceuticals: Q1 Earnings Snapshot
Baxter (BAX) delivered earnings and revenue surprises of 22.92% and 1.47%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
/PRNewswire/ -- Totus Medicines, the drug discovery and development company committed to ending the era of untreatable disease, announced today the appointment...